Where Particles Are Granulated Patents (Class 424/470)
  • Patent number: 10278925
    Abstract: Compositions for reducing the frequency of urination and methods of manufacture of the compositions are disclosed. One method of manufacture include the steps of forming a first mixture comprising a first active ingredient comprising one or more analgesic, coating the first mixture with a first delayed-release coating to form a first component, forming a second mixture comprising a second active ingredient comprising one or more analgesic agents, coating the second mixture with a second delayed-release coating to form a second component, and combining the first component with the second component to form a third mixture.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: May 7, 2019
    Assignee: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. Dill
  • Patent number: 10076516
    Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: September 18, 2018
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred Tonelli
  • Patent number: 9993433
    Abstract: The present invention relates to prolonged release pharmaceutical dosage forms, the manufacture thereof as well as their use for administration to human beings.
    Type: Grant
    Filed: May 10, 2011
    Date of Patent: June 12, 2018
    Assignee: Euro-Celtique S.A.
    Inventors: Geoffrey Gerard Hayes, Hassan Mohammad, Harjit Tamber, Malcolm Walden
  • Patent number: 9956194
    Abstract: This application relates to pharmaceutical compositions, comprising solabegron that are useful for the treatment of lower urinary tract symptoms such as, for example, overactive bladder and prostate disorders. Additionally, this application relates to methods for treating lower urinary tract symptoms utilizing the pharmaceutical compositions, comprising solabegron. In some embodiments, the pharmaceutical compositions, comprising solabegron comprise a dual release drug delivery system.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: May 1, 2018
    Assignee: Velicept Therapeutics, Inc.
    Inventors: Eliot Ohlstein, Raymond E. Stevens, Jr., H. Jeffrey Wilkins
  • Patent number: 9833510
    Abstract: A solid or semi-solid pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient having a shorter therapeutically effective plasma concentration duration, such as phenylephrine, and methods of administering the same are provided. This method provides improved therapeutic effect, in particular pain relief along with decongestant relief, over extended time periods.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: December 5, 2017
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Der-Yang Lee, Robert Shen, Jen-Chi Chen, Vincent Chen
  • Patent number: 9820824
    Abstract: A method for treating a site within a patient from which tissue has been removed includes providing at least one press-formed marker body formed of polysaccharide and a suitable binder; and placing the at least one of the press-formed marker body within the site where tissue has been removed so as to provide hemostasis therein.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: November 21, 2017
    Assignee: SenoRx, Inc.
    Inventors: Michael L. Jones, Paul Lubock
  • Patent number: 9642811
    Abstract: An abuse deterrent immediate release biphasic matrix solid dosage form that releases the drug at a desired rate for quick onset of action when a single unit or prescribed units of the dosage form are orally administered but exhibits a reduced rate of release when more than the prescribed number of units, are administered.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: May 9, 2017
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Nitin Bhalachandra Dharmadhikari, Yashoraj Rupsinh Zala, Dilip Shanghvi
  • Patent number: 9308164
    Abstract: A pharmaceutical dosage form which comprises two or more different hyoscyamine formulations, at least one of the formulations being an immediate release hyoscyamine formulation and at least one other one being a controlled release hyoscyamine formulation. This abstract is neither intended to define the invention disclosed in this specification nor intended to limit the scope of the invention in any way.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: April 12, 2016
    Assignee: Sovereign Pharmaceuticals, LLC
    Inventors: Viswanathan Srinivasan, Ralph Brown, David Brown, Himanshu Patel, Juan Carlos Menendez, Somphet Peter Suphasawud
  • Patent number: 9283211
    Abstract: The disclosure teaches counter-intuitive methods for treating stomatitis using oral mTOR inhibiting preparations such as preparations of microcapsules and nanoparticles including an inhibitor of the mammalian target of rapamycin. The methods, preparations and other teachings are useful in various respects, especially for assisting in the treatment, prevention and management of stomatitis in feline subjects and, most especially, the treatment and management of Feline Chronic Gingivo-Stomatitis (FCGS), with secondary applications also related to management of gingivitis and autoimmune mucosal disorders. Disclosed embodiments illustrate multi-week dosing regimens and also address needs for alternative preparations or manufacturing processes that ensure efficacy while improving other performance characteristics such as storage stability, biodistribution, dosage cost, etc.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: March 15, 2016
    Assignee: Rapamycin Holdings, LLC
    Inventor: Dana M Vaughn
  • Patent number: 9095594
    Abstract: Pharmaceutical compositions and methods for treating or preventing bacterial infections are disclosed. The pharmaceutical compositions typically comprise pharmaceutically effective amount of: (a) at least one beta-lactam antibiotic or a pharmaceutically acceptable salt thereof, (b) sulbactam or a pharmaceutically acceptable salt thereof, and (c) at least one beta-lactamase inhibitor or a pharmaceutically acceptable salt thereof, with the provision that the beta-lactamase inhibitor is not sulbactam.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: August 4, 2015
    Assignee: Wockhardt Ltd.
    Inventors: Sachin Subhash Bhagwat, Mahesh Vithalbhai Patel
  • Patent number: 9089607
    Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: July 28, 2015
    Assignee: Impax Laboratories, Inc.
    Inventors: Ann Hsu, Jim H. Kou, Laman Lynn Alani
  • Patent number: 9089608
    Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: July 28, 2015
    Assignee: Impax Laboratories, Inc.
    Inventors: Ann Hsu, Jim H. Kou, Laman Lynn Alani
  • Patent number: 9050263
    Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: June 9, 2015
    Assignee: RedHill Biopharma Ltd.
    Inventors: Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
  • Publication number: 20150064250
    Abstract: The invention provides a tamper-resistant dosage form including a therapeutic agent-substrate complex embedded in a thermo-formable matrix; such that the complex includes at least one therapeutic agent bound to at least one substrate to form the therapeutic agent-substrate complex. The at least one substrate is being selected from the group consisting of a polyelectrolyte, an organic counter-ion, a pharmacologically inert organic component of a prodrug, an inclusion compound and an inorganic adsorbent; and the thermo-formable matrix includes one or more thermoplastic polymers and optionally at least one pharmaceutical additive.
    Type: Application
    Filed: January 17, 2014
    Publication date: March 5, 2015
    Applicant: ExxPharma Therapeutics LLC
    Inventors: Isaac Ghebre-Sellassie, Hibreniguss Terefe
  • Publication number: 20150064251
    Abstract: A tamper-resistant dosage form including a therapeutic agent-substrate complex embedded in a thermo-formable matrix; such that the complex includes at least one therapeutic agent bound to at least one substrate to form the therapeutic agent-substrate complex. The at least one substrate is being selected from the group consisting of a polyelectrolyte, an organic counter-ion, a pharmacologically inert organic component of a prodrug, an inclusion compound and an inorganic adsorbent; and the thermo-formable matrix includes one or more thermoplastic polymers and optionally at least one pharmaceutical additive.
    Type: Application
    Filed: July 3, 2014
    Publication date: March 5, 2015
    Inventor: Isaac Ghebre-Sellassie
  • Patent number: 8962022
    Abstract: The present invention is directed to compositions of taste-masked microparticles comprising a substituted benzhydrylpiperazine coated and a taste-masking layer comprising a water-insoluble polymer and a gastrosoluble polymer, and methods of making such taste-masked microparticles. The present invention is also directed to stable orally disintegrating compositions comprising taste-masked microparticles of a substituted benzhydrylpiperazine and rapidly dispersing granules, and methods of making such orally disintegrating compositions.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: February 24, 2015
    Assignee: Aptalis Pharmatech, Inc.
    Inventor: Gopi Venkatesh
  • Patent number: 8956650
    Abstract: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 ?m, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: February 17, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Motohiro Ohta, Eiji Hayakawa, Kunio Ito, Sanji Tokuno, Kiyoshi Morimoto, Yasushi Watanabe
  • Patent number: 8945618
    Abstract: An intrabuccally rapidly disintegrating tablet which is manufactured by a simple method, has an enough practical hardness and is rapidly disintegrated in the buccal cavity and its production method. The intrabuccally rapidly disintegrating tablet is produced by growing a powder material into a granulated material with a fixed particle diameter, the powder material including a sugar alcohol or a saccharide as main ingredient, each of which is first particle having an average particle diameter of not more than 30 ?m, by mixing thus obtained granulated material with an active ingredient and a disintegrant, and by compressing the mixture into a predetermined shape.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: February 3, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Motohiro Ohta, Eiji Hayakawa, Kunio Ito, Sanji Tokuno, Kiyoshi Morimoto, Yasushi Watanabe
  • Patent number: 8927017
    Abstract: A method for preparing a gabapentin granulate comprising melt granulating gabapentin with polyethylene glycol having a melting point comprised between 50 and 80° C.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: January 6, 2015
    Assignee: ZAMBON S.p.A.
    Inventors: Luca Rampoldi, Alessandro Grassano
  • Patent number: 8927014
    Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a superabsorbent material. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material creates a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: January 6, 2015
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
  • Patent number: 8927013
    Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles. The composition further comprises a superabsorbent material disposed within the first layer, the second layer, or both the first layer and the second layer. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the composition.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: January 6, 2015
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
  • Patent number: 8920834
    Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a first layer and a second layer. The core comprises a superabsorbent material (for example, polycarbophil), and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to create a hard gel that traps the microparticles. The hard gel and microparticles provide controlled release of the pharmaceutically active agent. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: December 30, 2014
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara
  • Patent number: 8920833
    Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the coreswells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: December 30, 2014
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara
  • Patent number: 8911781
    Abstract: A novel patient-convenient, cost effective pharmaceutical composition, comprising of thiazolidinediones and biguanide for controlling hyperglycemia manufactured as multilayer tablet and its process of manufacturing, for immediate release of thiazolidinediones or thiazolidinediones and biguanide and prolonged release of the biguanide only, the tablet comprising of minimum two layers wherein one outer layer comprises of a mixture of excipients and thiazolidinediones or thiazolidinediones and biguanide allowing immediate release of thiazolidinediones or thiazolidinediones and biguanide respectively and the other layer arranged in contact with the immediate release layer which comprises of a novel composition of excipients and a minimum one or more non-biodegradable, inert polymer(s) and the biguanide allowing pH independent prolonged release of the biguanide up to a period of 8-12 hours. The tablets are for once a day dosing.
    Type: Grant
    Filed: October 14, 2002
    Date of Patent: December 16, 2014
    Assignee: Inventia Healthcare Private Limited
    Inventors: Amit Krishna Antarkar, Rajendra Ghanshamlal Lala, Nirav Mahendra Kamdar, Parag Narayan Gadkari, Maya Janak Shah, Janak Ramanlal Shah
  • Patent number: 8877241
    Abstract: A composition for controlled release of an opioid from a pharmaceutical composition, the method comprises controlling the release of at least one opioid into an aqueous medium by erosion of at least one surface of a pharmaceutical composition comprising I) a matrix composition comprising a) polymer or a mixture of polymers, b) an opioid and, optionally, c) one or more pharmaceutically acceptable excipients, and (i) a coating. The matrix composition has a conus-like shape so the surface area exposed to the aqueous medium increases at least during initial erosion of the matrix composition, and the dissolution of the opioid—when tested in a Dissolution Test as described herein with or without application of sinkers-results in a zero order release of at least 80% of the opioid contained in the composition. Such compositions are especially suitable for controlled release of an opioid to obtain a delayed peak concentration and a prolonged therapeutically effective plasma concentration upon oral administration.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: November 4, 2014
    Assignee: Egalet Ltd.
    Inventors: Gina Fischer, Daneil Bar-Shalom, Lillian Slot, Christine Andersen
  • Patent number: 8877249
    Abstract: A dosage form for controlled release is produced from a composition comprising a granular material having a mean particle diameter of 150 to 350 micrometers and a compactibility resulting in a compact with a tensile strength of at least 1.7 MPa when the granular material is subjected to a compaction pressure of 266 MPa, at least 80 percent of the granular material being a water-soluble cellulose ether, water-soluble cellulose ester, an alkylene oxide homo- or copolymer, or a blend thereof; and an active ingredient.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: November 4, 2014
    Assignee: Dow Global Technologies LLC
    Inventors: Tim D. Cabelka, Akshay Bellare, Ka Chun A. Chan, Tina P. Dasbach, Kacee B. Ender, Karl V. Jacob, Robert E. Scheid, Jr.
  • Patent number: 8877238
    Abstract: Film-coated tablet, consisting of a tablet core with a film coating, or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound, preferably imatinib or a pharmaceutically acceptable salt of imatinib, preferably imatinib monomethanesulfonate, wherein (i) the tablet cores and the granules have been produced by pressing of the starting materials and, prior to pressing of the starting materials, at least one of them has been dry-granulated, preferably compacted; (ii) the tablet cores and granule cores contain the active ingredient in a proportion of 25% by weight to 80% by weight, based on the total weight of the tablet cores or granule cores, together with (iii) at least one filler-binder, and optionally contain other additives; and (iv) the mean particle size distribution of at least 80% of the active ingredient is in the range from 0.01 mm to 1.0 mm.
    Type: Grant
    Filed: May 6, 2011
    Date of Patent: November 4, 2014
    Assignee: Siegfried International AG
    Inventors: Lambert Tillmann Röhrich, Beat W. Müller
  • Patent number: 8865219
    Abstract: The invention concerns coated granules including (A) at least one amine-containing pharmacological active principle, preferably as an acid addition salt, the pharmacological active principle being complexed by low cation-exchange resin containing carboxylic acid groups (COO?), and (B) at least 15 wt. %, based on the total weight of the active principle/low cation-exchange resin complex, of at least one hydrophilic adsorbent, the mixture of the components (A) and (B) being coated with a gastrosoluble polymer. The invention also concerns a method for preparing such granules, as well as orodispesible tablets containing such granules.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: October 21, 2014
    Assignee: Ethypharm
    Inventors: Mahendra B. Chaudhari, Edouard Gendrot
  • Patent number: 8846085
    Abstract: A directly tabletable ibuprofen formulation comprising a) 50-99% by weight of crystalline ibuprofen, b) 1-15% by weight of a finely divided excipient with a surface area of at least 100 m2/g, and c) 0-40% by weight of further excipients, with the proviso that the total amount of components a) to c) corresponds to 100% by weight, where at least 50% of the surface of the ibuprofen crystals are covered with the finely divided excipient.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: September 30, 2014
    Assignee: BASF SE
    Inventors: Kathrin Meyer-Boehm, Karl Kolter, Anisul Quadir
  • Patent number: 8846084
    Abstract: The present invention relates to controlled release compositions of Zolpidem or pharmaceutically acceptable salts thereof adapted to release Zolpidem over a predetermined time period, according to a monophasic and/or a biphasic profile of dissolution. The present invention also relates to monolithic matrix based formulations of Zolpidem or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: September 30, 2014
    Assignee: Wockhardt Ltd
    Inventors: Prashant Manohar Mandaogade, Venkatesh Madhavacharya Joshi, Girish Kumar Jain
  • Patent number: 8747896
    Abstract: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least one sustained release polymer, as well as a method for its preparation.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: June 10, 2014
    Assignee: BioAlliance Pharma
    Inventors: Dominique Costantini, Caroline Lemarchand
  • Patent number: 8722083
    Abstract: Various fenofibrate compositions include a plurality of first granules having a high bioavailability in vivo, and a plurality of second granules having a low bioavailability in vivo. The first granules may comprise fenofibrate, from 0.3% to 10% by weight of the first granules of a first surfactant, and a first water soluble or water dispersible cellulose derivative, and the second granules may comprise fenofibrate, from 0% to 0.25% by weight of the second granules of a second surfactant, and a second water soluble or water dispersible cellulose derivative.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: May 13, 2014
    Assignee: Mylan, Inc.
    Inventors: Sarat C. Chattaraj, Glenn Allen Redelman, Andrew Alan Shaw
  • Patent number: 8722133
    Abstract: The present invention herein provides an imidafenacin-containing orally rapidly disintegrating tablet which is excellent in the photostability. The present invention comprises the steps of: (A) granulating imidafenacin together with starch to thus give a granulated product having an imidafenacin concentration ranging from 0.001 to 3% by mass and a starch concentration ranging from 40 to 99.999% by mass; (B) covering the granulated product prepared in the step (A) with a non-cellulosic coating agent; and (C) blending the granulated product obtained in the preceding step (B) with an excipient and a disintegrating agent and then forming the resulting mixture into a tablet according to the compression molding technique.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: May 13, 2014
    Assignee: Kyorin Pharmaceutical Co., Ltd.
    Inventors: Toshihiro Ishizaki, Yoshinobu Aoki
  • Patent number: 8703191
    Abstract: Controlled-release tablets exhibiting excellent storage stability are achieved by granulating a pharmaceutically active agent with a hydroxyalkylcelluose, blending the resulting granules with an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which may be optionally coated, such as with an enteric coating composition, to provide delayed release and/or to enhance stability of the active agent.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: April 22, 2014
    Assignee: Intelgenx Corp.
    Inventors: Horst G. Zerbe, Nadine Paiement
  • Patent number: 8691270
    Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 8, 2014
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara
  • Patent number: 8691272
    Abstract: A multilayer oral dosage form that provides controlled release of an active compound includes a non-erodible core containing a pharmaceutically active compound and/or a nutritionally active compound, and at least one release-modulating layer laminated to each side of the core layer. The dosage form can be prepared using simple, inexpensive tablet compression techniques.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: April 8, 2014
    Assignee: Intelgenx Corp.
    Inventors: Horst G. Zerbe, Nadine Paiement, Pompilia Lspas-Szabo
  • Patent number: 8685447
    Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. A second layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles. The composition further comprises a superabsorbent material disposed within the first layer, the second layer, or both the first layer and the second layer. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the composition.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: April 1, 2014
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
  • Patent number: 8658207
    Abstract: The present invention provides pharmaceutical release systems comprising an therapeutically effective amount of flibanserin and at least one pharmaceutically acceptable excipient, characterized in that said pharmaceutical release systems exhibit a pharmacokinetic profile that is characterized by an average maximum flibanserin plasma concentration Cmax lower than 300 ng/mL, preferably lower than 200 ng/mL after administration of a single dose to healthy volunteers in fasted state or directly after a meal.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: February 25, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Wolfram Eisenreich, Thomas Friedl, Florian Sommer, Nantharat Pearnchob, Karl G. Wagner
  • Patent number: 8637079
    Abstract: A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which is useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts: (1) the first part containing compound (I) or a salt thereof and, as the first excipient, sugar or sugar alcohol; and (2) the second part containing pioglitazone or a salt thereof and, as the second excipient, sugar or sugar alcohol.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: January 28, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Kenji Nakamura, Kenichiro Kiyoshima, Junya Nomura
  • Patent number: 8617596
    Abstract: A process is provided for efficiently producing sustained-release tablets having superior sustained-release properties capable of inhibiting the initial elution of a drug and allowing the drug to be completely eluted after a prescribed amount of time has elapsed. A process for producing sustained-release tablets comprising: dry granulating a mixture composed of a hydroxyalkyl cellulose (A) having a viscosity of 1 to 50 mPa·s in a 2% by mass aqueous solution at 20° C., a hydroxyalkyl cellulose (B) having a viscosity of 100 mPa·s or more in a 2% by mass aqueous solution at 20° C., an active ingredient and an additive, and forming the resulting granules into tablets.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: December 31, 2013
    Assignee: Nippon Soda Co., Ltd.
    Inventors: Takeshi Honma, Kenji Furukawa
  • Patent number: 8568767
    Abstract: The present invention provides a chewable composition containing granules of water-soluble dietary fiber. The chewable composition has highly agreeable organolpetic properties and is consumable without the need of an ingestion aid.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: October 29, 2013
    Assignee: Novartis AG
    Inventors: Nils William Ahlgren, Ronald Lee Dahl, Monte Lee Friesen, Alexander Mark Schobel
  • Patent number: 8557283
    Abstract: The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: October 15, 2013
    Assignee: Impax Laboratories, Inc.
    Inventors: Ann Hsu, Jim H. Kou, Laman Lynn Alani
  • Patent number: 8551915
    Abstract: The present invention provides a product for agricultural use in the form of granules or pellets, characterized by comprising at least 30% (w/w) of vinasses and/or sludge measured as a dry extract of vinasses and/or sludge, and an organic or inorganic solid support. In addition, the present invention provides a procedure for producing said product, its use in agriculture, stockbreeding or as biodiesel.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: October 8, 2013
    Assignee: HPD Process Engineering, S.A.
    Inventor: Daniel Irisarri Navalpotro
  • Patent number: 8545886
    Abstract: The invention is directed to a Pharmaceutical extended release system, particularly for oral administration, of a pH-dependent water-soluble active substance, comprising or essentially consisting of a) flibanserin or a pharmaceutically acceptable derivative thereof as active substance; b) one or more pharmaceutically acceptable pH-dependent polymers; c) one or more pharmaceutically acceptable pH-independent polymers; d) one or more pharmaceutically acceptable acids; and e) optionally one or more additives. The present invention provides a release profile of flibanserin which is independent on the pH in the gastrointestinal tract when administered orally resulting in a significantly improved bioavailability.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: October 1, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Wolfram Eisenreich, Thomas Friedl
  • Patent number: 8535716
    Abstract: A pharmaceutical composition is provided that includes an active ingredient in the form of a powder or granule, a water soluble high molecular weight excipient and a water insoluble hydrophilic amphiphilic excipient. These ingredients are solution mixed and dried to form a modified pharmaceutical ingredient in simultaneous contact with both the water soluble high molecular weight excipient and the water insoluble hydrophilic amphiphilic excipient. Adjuvants are compacted about the modified pharmaceutical ingredient as well as a release control agent. The release control agent being present at levels from 1 to 40 total weight percent of the pharmaceutical composition.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: September 17, 2013
    Assignee: TSRL, Inc.
    Inventors: John Hilfinger, Jae Seung Kim, Paul Kijek
  • Patent number: 8535799
    Abstract: A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low aqueous solubility and/or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5° C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and/or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material.
    Type: Grant
    Filed: February 27, 2007
    Date of Patent: September 17, 2013
    Assignee: Veloxis Pharmaceuticals A/S
    Inventors: Anders Burr, Michiel Ringkjøbing-Elema, Jannie Egeskov Holm, Per Holm, Birgitte Møllgaard, Kirsten Schultz
  • Patent number: 8512744
    Abstract: Sustained release micropellets showing a stable controlled-release of a drug without being affected by the changes in pH value etc., characterized by being produced by coating core particles with a layer containing a water-soluble drug and further forming a film layer containing a water-insoluble polymer compound and a plasticizer on the thus obtained particles, locating a water-soluble filler layer between the water soluble drug-containing layer and the film layer, and having an average particle size of 300 ?m or less; medicinal compositions containing these micropellets; and a process for producing the same.
    Type: Grant
    Filed: August 16, 2007
    Date of Patent: August 20, 2013
    Assignee: Fujimoto Co., Ltd.
    Inventors: Fumio Yoneda, Fumiya Hamano, Eisaku Kitano, Tetsuya Hosono
  • Publication number: 20130209560
    Abstract: This disclosure relates to a sustained-release oral dosage form suitable for twice-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydrocodone. The dosage form can have a release profile such that 6 hours following administration, less than about 80 percent of the hydrocodone is released. In addition, the dosage form may have alcohol and/or crush resistance.
    Type: Application
    Filed: February 23, 2011
    Publication date: August 15, 2013
    Applicant: CIMA LABS Inc.
    Inventors: Ehab Hamed, Carrie Kraling
  • Patent number: 8486449
    Abstract: Disclosed is a misuse preventative, controlled release composition in the form of a multilayered oral dosage form. A first layer contains a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed therein. The second layer, which can be adjacent the first layer comprises a pharmaceutically active agent that can be the same or different from the pharmaceutically active agent in the microparticles in the first layer. The composition further comprises a superabsorbent material (for example, polycarbophil) disposed within the first layer, the second layer, or both the first layer and the second layer. When intact, the pharmaceutically active agent is released from the second layer faster than the pharmaceutically active agent in the first layer.
    Type: Grant
    Filed: December 16, 2009
    Date of Patent: July 16, 2013
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Ali Bichara
  • Patent number: 8486448
    Abstract: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both the core and the coat. When crushed, either intentionally or accidentally, and exposed to an aqueous medium, the superabsorbent material present in the core swells to encapsulate the microparticles, which remain substantially intact thereby retarding the release of the pharmaceutically active agent from the formulation. Also disclosed is a method of using the misuse preventative, controlled release formulation to deliver a pharmaceutically active agent to a mammal, for example, a human, in need thereof.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: July 16, 2013
    Assignees: Paladin Labs Inc., Paladin Labs (Barbados) Inc., Paladin Labs Europe Limited
    Inventors: Miloud Rahmouni, Angela Ferrada, Fouzia Soulhi, Sonia Gervais, Vinayak Sant, Damon Smith, Frederic Duffayet, Shams Rustom, Ali El-Jammal, Jean-Michel Ndong, Bobby-Ernst Boursiquot, Ali Bichara